Research programme: C1 inhibitors - Johnson & Johnson Pharmaceutical Research and Development

Drug Profile

Research programme: C1 inhibitors - Johnson & Johnson Pharmaceutical Research and Development

Alternative Names: C1 inhibitors research programme - 3-Dimensional Pharmaceuticals; Complement C1 esterase inhibitors research programme - 3-Dimensional Pharmaceuticals

Latest Information Update: 14 Jul 2006

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Class Small molecules
  • Mechanism of Action Complement C1s inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Lupus vulgaris; Psoriasis; Reperfusion injury; Rheumatoid arthritis

Most Recent Events

  • 14 Jul 2006 No development reported - Preclinical for Lupus in USA (IV)
  • 14 Jul 2006 No development reported - Preclinical for Reperfusion injury in USA (IV)
  • 14 Jul 2006 No development reported - Preclinical for Psoriasis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top